Entering text into the input field will update the search result below

Checking In On Cortexyme


Bacteria Intestine
Photo by wildpixel/iStock via Getty Images

There's no need to talk about it, because the truth of what one says lies in what one does." - Bernhard Schlink

Today we take an in-depth look at a 'Tier 4' biotech

Live Chat on The Biotech Forum has been dominated by discussion of these types of buy-write opportunities over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE.

This article was written by

Bret Jensen profile picture

Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.

Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.

Analyst’s Disclosure: I am/we are long CRTX. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (21)

Delmar Price profile picture
CRTX trial, even though it failed showed encouraging results.
@Bret Jensen You are far and away my #1 contra-indicator. I don't know what your diligence process is, or how you pick a stock to promote, but you are very consistent. Keep it up, my short book appreciates it!
I have to agree. He is the kiss of death.
I wrote a more recent article on Cortexyme. I don't think it is to risky at this stage. Their approach paired with also working on a treatment for periodontal disease de-risked the investment in my view: www.shovel-stocks.com/...
Very interesting
Bret Jensen profile picture
Cortexyme (CRTX +23.0%) expects top-line data from its pivotal phase 2/3 GAIN trial of its Alzheimer's candidate atuzaginstat (COR388) by mid-November.
The candidate targets the bacteria P. gingivalis. During last month's AAIC 2021 conference, the company released data showing that P. gingivalis is linked to increased levels of a tau protein, an biomarker of Alzheimer’s disease.
“We believe positive data from the GAIN Trial could fundamentally shift the paradigm of neurodegeneration research and disease-modifying treatment in the Alzheimer’s field and we intend to rapidly pursue collaboration with the FDA for the benefit of patients," Chief Medical Officer Michael Detke said in a news release.
The GAIN Trial has enrolled 643 patients with mild-to-moderate Alzheimer’s. It is powered at ~90% to show a 50% slowing of decline as measured by the cognitive and functional co-primary clinical endpoints of ADAS-Cog11 and ADCS-ADL.
In Q2 2021, Cortexyme's GAAP EPS beat by a nickel.
Delmar Price profile picture
@Bret Jensen I started a position conservatively with options, which are lucrative however there isn't much interest in them.
@Bret Jensen Thanks for the article Bret! Just a quick question, what do you mean by "It is powered at ~90% to show a 50% slowing of decline"? Is CRTX hoping to report a slow down of 50% in the decline in cognition?
TraderLawJF profile picture
I passed on this when I saw the liver issues and your article....sigh
@TraderLawJF you still have time until Mid Nov. Any price below 100 per share will be cheap when we are in Nov.
TraderLawJF profile picture
@shovel-stocks What happened to liver concerns?
@TraderLawJF As far as I recall, those were reversible and non-life-threatening, but enough for the FDA to pull the plug on a continuation of the open label. Correct me if I'm wrong.
hall monitor profile picture
"CEO Casey Lynch has been a recent seller of Cortexyme stock, raising ~$2.6 million through the disposition of 70,000 shares in multiple transactions since February 1, 2021. It should be noted that he still owns north of 1.1 million shares."

Ms. Lynch may be surprised to learn you think she is a male.
The Insiders Forum profile picture
Cortexyme (NASDAQ:CRTX): Q1 GAAP EPS of -$0.78 beats by $0.02.
Cash, cash equivalents, and short and long-term marketable securities as of March 31, 2021 were $170.8 million and include approximately $117.6 million of net proceeds raised in Cortexyme’s private placement offering completed in February 2020. Cortexyme expects its cash position to be sufficient to fund its operating and capital expenditures through 2023.
Gordon Gecko was a Commie profile picture
@Bret Jensen thanks, nice writeup. I follow this one quite closely and think it is an example where the science is telling quite a compelling story. Unlike all the other AD approaches currently in trials, CRTX has a complete theory of the pathogenesis of AD. CRTX has pretty clearly shown all of Koch's postulates that the pathogen causes the disease. The Pg / gingipain theory can explain essentially all known physiological phenomena associated with AD (amyloid plaques, pTau tangles, neurodegeneration) and they can fully explain the genetic risk associated with APOE. It really has not gotten much attention in the media nor from wall street, but I predict the GAIN trial results will get a lot of attention come Q4. Of course we still need to see that data, but connecting the dots-- I like the odds.
@Gordon Gecko was a Commie Yep, me too. In addition, I like the thin float. Once data is released in Q4 and it is good, the new money flowing in will not have a lot of shares to buy which in turn squeezes price upwards
Bret Jensen profile picture
@Gordon Gecko was a Commie I hope for society's sake, you are right....would be a huge win.
fffgp profile picture
Nice article. Reminds me why I think it important to floss and use mouth wash. Nice premiums on the stock.
Most everything biotech has dived into the basement. Possibly due to the Biden Administration considering rescinding patent protection for covid vaccines. Without patent protection, new medicines would evaporate and health care would return to the middle ages. Insanity. There would be zero vaccines when China releases the next covid virus.
Bret Jensen profile picture
@dixie Also sector week from Mid-February (after euphoria from JPM Healthcare conference in SF the prior month and ASCO in Chicago) in early June historically
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About QNCX Stock

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on QNCX

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.